Novartis (NYSE:NVS) subsidiary Alcon said it acquired Tear Film Innovations for an undisclosed amount. San Diego-based TFI makes the iLux system, which is designed to treat blocked meibomian glands in eyelids. The company had raised a total of $18 million in two rounds in as many years, split evenly between the two. iLux won 510(k) clearance from the FDA […]
tearfilminnovations
New eye health companies gain funders’ focus
Startups pioneering less-invasive technologies to treat common eye diseases are changing the outlook for both patients and the industry. A new study by CB Insights revealed that investors have been pouring money into smaller companies in 2017 and 2018, with some FDA approvals to begin marketing their technologies and treatments. These firms are eyeing conditions […]
Tear Film Innovations closes $9m Series B
Eye-care focused device developer Tear Film Innovations said today it closed an $8.5 million Series B to support its flagship iLux system designed to treat blocked meibomian glands in eyelids. The iLux system is currently under investigational device review by the FDA, and is designed to allow for the in-office treatment of blocked meibomian glands through targeted […]
Eye-focused dev Tear Film Innovations closes $9m Series A
Eye-care focused device developer Tear Film Innovations said today it closed a $9 million Series A preferred stock round to support its iLux system designed to treat blocked meibomian glands in eyelids. The round was led by Visionary Ventures Fund and Tigris Ventures, the San Diego, Calif.-based company said. “There is no question the prevalence […]